AQP4 and myeloid sarcoma: For example, one study from the UK in 26 AQP4 ab seropositive NMOSD (63% of whom had brain T2 lesions and 16% met Barkhof criteria) and 50 RRMS patients replicated a few key features in both conditions that appeared to be discriminative, among them a smaller lesion size and fewer numbers in NMOSD as compared to MS, and MS exhibited a greater coherence of lesion location (most likely to occur adjacent to the posterior of the body of the lateral ventricle in the parietal white matter) (187).